Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.90
Bid: 76.80
Ask: 78.30
Change: 0.00 (0.00%)
Spread: 1.50 (1.953%)
Open: 77.90
High: 0.00
Low: 0.00
Prev. Close: 77.90
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kerry to acquire Lactase Enzymes Business

12 Dec 2023 16:13

RNS Number : 5363W
Kerry Group PLC
12 December 2023

12 December 2023

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP

Kerry to acquire Lactase Enzymes Business

Kerry Group plc ("Kerry"), the global taste & nutrition company, announces it has entered into a definitive agreement to acquire part of the global lactase enzyme business of Chr. Hansen Holding A/S ("Chr. Hansen") and Novozymes A/S ("Novozymes") (together the "Lactase Enzymes Business") on a carve out basis¹. This acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger approval process.

The Lactase Enzymes Business which includes NOLA® Products, further enhances Kerry's biotechnology solutions capability following the acquisitions of c-LEcta and Enmex². This acquisition adds enzyme technology which helps create lactose-free and sugar reduced dairy products, while preserving their authentic clean taste. Global demand for lactase is being driven by increased awareness of lactose intolerance, while many consumers are also choosing lactose-free for lifestyle and health reasons.

The Lactase Enzymes Business had attributable revenue of approximately ?40m in 2022 with sales in over 50 countries. Total consideration is ?150m subject to routine closing adjustments, with the acquisition expected to close in the first half of 2024.

¹ Acquisition comprises certain trade and assets of Chr. Hansen's global lactase enzyme business and 100% of the share capital of Nuocheng Trillion Food (Tianjin) Co., Ltd, a Chinese subsidiary of Novozymes.

² Acquisition of c-LEcta GmbH completed in March 2022 and Enmex S.A. de C.V. in December 2021.

ENDS

About Kerry

Kerry is a world leading taste and nutrition partner for the food, beverage and pharmaceutical markets. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customers' complex challenges with differentiated solutions. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and to reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerry.com.

CONTACT INFORMATION

Investor Relations

Marguerite Larkin, Chief Financial Officer

+353 66 7182292 | investorrelations@kerry.ie

William Lynch, Head of Investor Relations

+353 66 7182292 | investorrelations@kerry.ie

Media

Catherine Keogh, Chief Corporate Affairs & Brand Officer

+353 45 930188 | corpaffairs@kerry.com

Website

www.kerry.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACQBLBDDDBBDGXD
Date   Source Headline
3rd Oct 202210:13 amRNSTotal Voting Rights
5th Sep 20221:04 pmRNSDirector/PDMR Shareholding
1st Sep 202210:08 amRNSTotal Voting Rights
30th Aug 20222:02 pmRNSKerry Acquisition Announcement
2nd Aug 202210:09 amRNSDirector/PDMR Shareholding
2nd Aug 20229:00 amRNSTotal Voting Rights
29th Jul 20227:00 amRNSKerry Group Interim Management Report 2022
1st Jul 20228:54 amRNSBlock listing Interim Review
1st Jul 20228:40 amRNSTotal Voting Rights
20th Jun 202210:23 amRNSHolding(s) in Company
1st Jun 202210:03 amRNSTotal Voting Rights
3rd May 202212:57 pmRNSTotal Voting Rights
28th Apr 20224:32 pmRNSDirectorate Change
28th Apr 20224:29 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 Interim Management Statement 2022
4th Apr 20221:42 pmRNSStatement re Russian and Belarus Operations
1st Apr 202211:22 amRNSTotal Voting Rights
25th Mar 202212:55 pmRNSNotice of AGM
16th Mar 20221:50 pmRNSHolding(s) in Company
16th Mar 20221:39 pmRNSDirector/PDMR Shareholding
15th Mar 20224:45 pmRNSDirector/PDMR Shareholding
11th Mar 20224:03 pmRNSDirector/PDMR Shareholding
11th Mar 20223:59 pmRNSDirector/PDMR Shareholding
11th Mar 20223:55 pmRNSDirector/PDMR Shareholding
11th Mar 202212:13 pmRNSAnnual Financial Report
1st Mar 20229:50 amRNSTotal Voting Rights
25th Feb 20223:14 pmRNSDirector/PDMR Shareholding
16th Feb 20227:00 amRNSPreliminary Statement of Results 31 December 2021
15th Feb 202211:29 amRNSNotice of Results and AGM
15th Feb 20227:00 amRNSKerry – strategic biotechnology acquisitions
1st Feb 20222:21 pmRNSTotal Voting Rights
4th Jan 20223:00 pmRNSBlock listing Interim Review
4th Jan 202212:00 pmRNSTotal Voting Rights
13th Dec 202110:31 amRNSDirectorate Change
9th Dec 202112:17 pmRNSDirector/PDMR Shareholding
1st Dec 202112:26 pmRNSTotal Voting Rights
29th Nov 20211:28 pmRNSDirector/PDMR Shareholding
24th Nov 20215:41 pmRNSKerry - EUR750m Sustainability-Linked Notes
1st Nov 202111:20 amRNSTotal Voting Rights
27th Oct 20217:00 amRNSQ3 Interim Management Statement 2021
13th Oct 20217:00 amRNSKerry Strategic Update – Capital Markets Day
1st Oct 20219:20 amRNSTotal Voting Rights
27th Sep 20217:00 amRNSKerry Completes Sale of Meats & Meals Business
14th Sep 20217:00 amRNSKerry completes acquisition of Niacet
2nd Sep 202111:54 amRNSHolding(s) in Company
1st Sep 202111:22 amRNSHolding(s) in Company
1st Sep 202111:02 amRNSTotal Voting Rights
18th Aug 20214:11 pmRNSDirector/PDMR Shareholding
6th Aug 20214:20 pmRNSHolding(s) in Company
3rd Aug 202111:17 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.